Sign In   |   Register
News: Publications

New editorial on the highs and lows of cardiovascular disease prevention

Thursday 8 February 2018   (0 Comments)
Share |

In 2017, three major trials provided important insights into cardiovascular disease prevention. The first of these, FOURIER with the PCSK9 inhibitor evolocumab, showed that lowering plasma levels of low-density lipoprotein cholesterol (LDL-C) beyond current goals significantly reduced cardiovascular events; moreover, there appeared to be no lower LDL-C threshold for clinical benefit. The much-awaited REVEAL study with anacetrapib, the most recent in the line of CETP inhibitors to be tested, showed modest benefit in reducing major coronary events in patients with stable atherosclerotic cardiovascular disease. However, anacetrapib was subsequently terminated due to uncertainty regarding the long-term consequences of adipose tissue accumulation seen with this agent.

Finally, CANTOS confirmed that targeting inflammation with the interleukin-1β monoclonal antibody canakinumab reduced cardiovascular events. Taken together, both FOURIER and CANTOS add evidence for a personalized medicine approach to cardiovascular disease prevention.

 To the editorial by Jane Stock >>


Membership Software Powered by YourMembership  ::  Legal